BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38290287)

  • 1. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes.
    Bull CJ; Hazelwood E; Legge DN; Corbin LJ; Richardson TG; Lee M; Yarmolinsky J; Smith-Byrne K; Hughes DA; Johansson M; Peters U; Berndt SI; Brenner H; Burnett-Hartman A; Cheng I; Kweon SS; Le Marchand L; Li L; Newcomb PA; Pearlman R; McConnachie A; Welsh P; Taylor R; Lean MEJ; Sattar N; Murphy N; Gunter MJ; Timpson NJ; Vincent EE
    EBioMedicine; 2024 Feb; 100():104977. PubMed ID: 38290287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study.
    Morales Berstein F; McCartney DL; Lu AT; Tsilidis KK; Bouras E; Haycock P; Burrows K; Phipps AI; Buchanan DD; Cheng I; ; Martin RM; Davey Smith G; Relton CL; Horvath S; Marioni RE; Richardson TG; Richmond RC
    Elife; 2022 Mar; 11():. PubMed ID: 35346416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.
    Leslie WS; Ford I; Sattar N; Hollingsworth KG; Adamson A; Sniehotta FF; McCombie L; Brosnahan N; Ross H; Mathers JC; Peters C; Thom G; Barnes A; Kean S; McIlvenna Y; Rodrigues A; Rehackova L; Zhyzhneuskaya S; Taylor R; Lean ME
    BMC Fam Pract; 2016 Feb; 17():20. PubMed ID: 26879684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.
    Lean MEJ; Leslie WS; Barnes AC; Brosnahan N; Thom G; McCombie L; Peters C; Zhyzhneuskaya S; Al-Mrabeh A; Hollingsworth KG; Rodrigues AM; Rehackova L; Adamson AJ; Sniehotta FF; Mathers JC; Ross HM; McIlvenna Y; Welsh P; Kean S; Ford I; McConnachie A; Messow CM; Sattar N; Taylor R
    Lancet Diabetes Endocrinol; 2019 May; 7(5):344-355. PubMed ID: 30852132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
    Lean ME; Leslie WS; Barnes AC; Brosnahan N; Thom G; McCombie L; Peters C; Zhyzhneuskaya S; Al-Mrabeh A; Hollingsworth KG; Rodrigues AM; Rehackova L; Adamson AJ; Sniehotta FF; Mathers JC; Ross HM; McIlvenna Y; Stefanetti R; Trenell M; Welsh P; Kean S; Ford I; McConnachie A; Sattar N; Taylor R
    Lancet; 2018 Feb; 391(10120):541-551. PubMed ID: 29221645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustered Mendelian randomization analyses identify distinct and opposing pathways in the association between genetically influenced insulin-like growth factor-1 and type 2 diabetes mellitus.
    Wang W; Tesfay EB; van Klinken JB; Willems van Dijk K; Bartke A; van Heemst D; Noordam R
    Int J Epidemiol; 2022 Dec; 51(6):1874-1885. PubMed ID: 35656699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis.
    Yarmolinsky J; Robinson JW; Mariosa D; Karhunen V; Huang J; Dimou N; Murphy N; Burrows K; Bouras E; Smith-Byrne K; Lewis SJ; Galesloot TE; Kiemeney LA; Vermeulen S; Martin P; Albanes D; Hou L; Newcomb PA; White E; Wolk A; Wu AH; Le Marchand L; Phipps AI; Buchanan DD; ; ; Zhao SS; Gill D; Chanock SJ; Purdue MP; Davey Smith G; Brennan P; Herzig KH; Järvelin MR; Amos CI; Hung RJ; Dehghan A; Johansson M; Gunter MJ; Tsilidis KK; Martin RM
    EBioMedicine; 2024 Feb; 100():104991. PubMed ID: 38301482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme.
    Xin Y; Davies A; Briggs A; McCombie L; Messow CM; Grieve E; Leslie WS; Taylor R; Lean MEJ
    Diabetologia; 2020 Oct; 63(10):2112-2122. PubMed ID: 32776237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
    Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
    Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of genetic variation to separate the effects of early and later life adiposity on disease risk: mendelian randomisation study.
    Richardson TG; Sanderson E; Elsworth B; Tilling K; Davey Smith G
    BMJ; 2020 May; 369():m1203. PubMed ID: 32376654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing causal associations of obesity and diabetes with kidney stones using Mendelian randomization analysis.
    Yuan S; Larsson SC
    Mol Genet Metab; 2021; 134(1-2):212-215. PubMed ID: 34454843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Obesity Cause Thyroid Cancer? A Mendelian Randomization Study.
    Fussey JM; Beaumont RN; Wood AR; Vaidya B; Smith J; Tyrrell J
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2398-407. PubMed ID: 32392279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).
    Corbin LJ; Hughes DA; Bull CJ; Vincent EE; Smith ML; McConnachie A; Messow CM; Welsh P; Taylor R; Lean MEJ; Sattar N; Timpson NJ
    Diabetologia; 2024 Jan; 67(1):74-87. PubMed ID: 37878066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial.
    Taheri S; Zaghloul H; Chagoury O; Elhadad S; Ahmed SH; El Khatib N; Amona RA; El Nahas K; Suleiman N; Alnaama A; Al-Hamaq A; Charlson M; Wells MT; Al-Abdulla S; Abou-Samra AB
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):477-489. PubMed ID: 32445735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of second primary cancers after a diagnosis of first primary cancer: A pan-cancer analysis and Mendelian randomization study.
    Ruan X; Huang D; Zhan Y; Huang J; Huang J; Ng AT; Tsu JH; Na R
    Elife; 2023 Nov; 12():. PubMed ID: 37917154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.
    ; Gregg EW; Jakicic JM; Blackburn G; Bloomquist P; Bray GA; Clark JM; Coday M; Curtis JM; Egan C; Evans M; Foreyt J; Foster G; Hazuda HP; Hill JO; Horton ES; Hubbard VS; Jeffery RW; Johnson KC; Kitabchi AE; Knowler WC; Kriska A; Lang W; Lewis CE; Montez MG; Nathan DM; Neiberg RH; Patricio J; Peters A; Pi-Sunyer X; Pownall H; Redmon B; Regensteiner J; Rejeski J; Ribisl PM; Safford M; Stewart K; Trence D; Wadden TA; Wing RR; Yanovski SZ
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):913-921. PubMed ID: 27595918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the causal relationships and mediating factors between depression, anxiety, panic, and atrial fibrillation: A multivariable Mendelian randomization study.
    Zhou H; Ji Y; Sun L; Wang Z; Jin S; Wang S; Yang C; Yin D; Li J
    J Affect Disord; 2024 Mar; 349():635-645. PubMed ID: 38211754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease.
    Mazidi M; Wright N; Yao P; Kartsonaki C; Millwood IY; Fry H; Said S; Pozarickij A; Pei P; Chen Y; Avery D; Du H; Schmidt DV; Yang L; Lv J; Yu C; Chen J; Hill M; Holmes MV; Howson JMM; Peto R; Collins R; Bennett DA; Walters RG; Li L; Clarke R; Chen Z;
    J Am Coll Cardiol; 2023 Nov; 82(20):1906-1920. PubMed ID: 37940228
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.